ArticleHeliyon2024

Cabozantinib prevents the progression of metabolic dysfunction-associated steatohepatitis by inhibiting the activation of hepatic stellate cell and macrophage and attenuating angiogenic activity.

Takuya Matsuda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.